In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Marinus Pharmaceuticals, Inc.. Trade Record

NASDAQ:MRNS Marinus Pharmaceuticals, Inc. stock gains 170.45% Exit Oct 9, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart MRNS Aug 9, 2017, priceSeries
About Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.

Trade Information
Trade Type
LONG
ReliabilityScore™
93.07
Entry Date
Aug 9, 2017
Entry Price
2.26
Sell Date
Oct 9, 2017
Sell Price
6.11
Net Gain
170.45%
Hold Time
42 Trading Days